ArticleBritish journal of pharmacology2001
Effect of vanilloid drugs on gastrointestinal transit in mice.
Article in British journal of pharmacology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 80 citations in OpenAlex.
- Endocannabinoid-related compounds in gastrointestinal diseases.Journal of cellular and molecular medicine · 2018Review
- Article
- Small Molecules from Nature Targeting G-Protein Coupled Cannabinoid Receptors: Potential Leads for Drug Discovery and Development.Evidence-based complementary and alternative medicine : eCAM · 2015Review
- Palmitoylethanolamide normalizes intestinal motility in a model of post-inflammatory accelerated transit: involvement of CB₁ receptors and TRPV1 channels.British journal of pharmacology · 2014Article
- Tibetan herbal formula Padma Digestin modulates gastrointestinal motility in vitro.World journal of gastrointestinal pharmacology and therapeutics · 2013Article
- Prejunctional and peripheral effects of the cannabinoid CB(1) receptor inverse agonist rimonabant (SR 141716).Naunyn-Schmiedeberg's archives of pharmacology · 2008Review
- Cannabidiol, extracted from Cannabis sativa, selectively inhibits inflammatory hypermotility in mice.British journal of pharmacology · 2008Article
- ThermoTRP channels in nociceptors: taking a lead from capsaicin receptor TRPV1.Current neuropharmacology · 2008Article
- The role of endocannabinoids in the regulation of gastric emptying: alterations in mice fed a high-fat diet.British journal of pharmacology · 2008Article
- Article
- Investigation on the relationship between cannabinoid CB1 and opioid receptors in gastrointestinal motility in mice.British journal of pharmacology · 2006Article
- The endocannabinoid system in the physiology and pathophysiology of the gastrointestinal tract.Journal of molecular medicine (Berlin, Germany) · 2005Review
- Effects of piperine, the pungent component of black pepper, at the human vanilloid receptor (TRPV1).British journal of pharmacology · 2005Article
- Role of intrinsic nitrergic neurones on vagally mediated striated muscle contractions in the hamster oesophagus.The Journal of physiology · 2003Article
- Inhibitory effect of palmitoylethanolamide on gastrointestinal motility in mice.British journal of pharmacology · 2001Article
- Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation.British journal of pharmacology · 2001Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
1. We have studied the effect of capsaicin, piperine and anandamide, drugs which activate vanilloid receptors and capsazepine, a vanilloid receptor antagonist, on upper gastrointestinal motility in mice. 2. Piperine (0.5 - 20 mg kg(-1) i.p.) and anandamide (0.5 - 20 mg kg(-1) i.p.), dose-dependently delayed gastrointestinal motility, while capsaicin (up to 3 mg kg(-1) i.p.) was without effect. Capsazepine (15 mg kg(-1) i.p.) neither per se affected gastrointestinal motility nor did it counteract the inhibitory effect of both piperine (10 mg kg(-1)) and anandamide (10 mg kg(-1)). 3. A per se non effective dose of SR141716A (0.3 mg kg(-1) i.p.), a cannabinoid CB(1) receptor antagonist, counteracted the inhibitory effect of anandamide (10 mg kg(-1)) but not of piperine (10 mg kg(-1)). By contrast, the inhibitory effect of piperine (10 mg kg(-1)) but not of anandamide (10 mg kg(-1)) was strongly attenuated in capsaicin (75 mg kg(-1) in total, s.c.)-treated mice. 4. Pretreatment of mice with N(G)-nitro-L-arginine methyl ester (25 mg kg(-1) i.p.), yohimbine (1 mg kg(-1), i.p.), naloxone (2 mg kg(-1) i.p.), or hexamethonium (1 mg kg(-1) i.p.) did not modify the inhibitory effect of both piperine (10 mg kg(-1)) and anandamide (10 mg kg(-1)). 5. The present study indicates that the vanilloid ligands anandamide and piperine, but not capsaicin, can reduce upper gastrointestinal motility. The effect of piperine involves capsaicin-sensitive neurones, but not vanilloid receptors, while the effect of anandamide involves cannabinoid CB(1), but not vanilloid receptors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.